Dermal toxicity study of rice bran supercritical CO2 extract in Sprague-Dawley rats

2015 ◽  
Vol 24 (3) ◽  
pp. 1167-1176
Author(s):  
Jae-Suk Choi ◽  
Eun Jin Cheon ◽  
Tae-Uk Kim ◽  
Woi-Sook Moon ◽  
Joo-Wan Kim ◽  
...  
2011 ◽  
Vol 31 (1) ◽  
pp. 26-32 ◽  
Author(s):  
P. Surekha ◽  
A. Sairam Kishore ◽  
A. Srinivas ◽  
G. Selvam ◽  
A. Goparaju ◽  
...  

2013 ◽  
Vol 32 (5) ◽  
pp. 385-394 ◽  
Author(s):  
Antoinette Y. Odendaal ◽  
Narendra S. Deshmukh ◽  
Tennille K. Marx ◽  
Alexander G. Schauss ◽  
John R. Endres ◽  
...  

This toxicological assessment evaluated the safety of a hydroethanolic extract prepared from Caralluma fimbriata (CFE), a dietary supplement marketed worldwide as an appetite suppressant. Studies included 2 in vitro genotoxicity assays, a repeated dose oral toxicity study, and a developmental study in rats. No evidence of in vitro mutagenicity or clastogenicity surfaced in the in vitro studies at concentrations up to 5000 μg of extract/plate (Ames test) or 5000 μg of extract/mL (chromosomal aberration test). No deaths or treatment-related toxicity were seen in the 6-month chronic oral toxicity study in Sprague-Dawley rats conducted at 3 doses (100, 300, and 1000 mg/kg body weight (bw)/d). The no observed effect level for CFE in this study was considered to be 1000 mg/kg bw/d. A prenatal developmental toxicity study conducted at 3 doses (250, 500, and 1000 mg/kg bw/d) in female Sprague-Dawley rats resulted in no treatment-related external, visceral, or skeletal fetal abnormalities, and no treatment-related maternal or pregnancy alterations were seen at and up to the maximum dose tested. CFE was not associated with any toxicity or adverse events.


2021 ◽  
pp. 112780
Author(s):  
Shu-Chieh Hu ◽  
Seonggi Min ◽  
Hyun-Ki Kang ◽  
Dong-Jin Yang ◽  
Mallikarjuna Basavarajappa ◽  
...  

2012 ◽  
Vol 1 (2) ◽  
Author(s):  
Mohd Saleh Ahmad Kamal ◽  
Ahmad Rohi Ghazali ◽  
Noral ‘Ashikin Yahya ◽  
Mohd Isa Wasiman ◽  
Zakiah Ismail

2016 ◽  
Vol 81 ◽  
pp. 275-283 ◽  
Author(s):  
A.M. Saillenfait ◽  
F. Marquet ◽  
J.P. Sabaté ◽  
D. Ndiaye ◽  
A.M. Lambert-Xolin

2020 ◽  
Vol 216 (1) ◽  
pp. 152730
Author(s):  
Nenggang Zhang ◽  
Asis K. Sarkar ◽  
Debananda Pati

2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Sae-Rom Yoo ◽  
Hyekyung Ha ◽  
Mee-Young Lee ◽  
Hyeun-kyoo Shin ◽  
Su-Cheol Han ◽  
...  

Ssanghwa-tang (SHT), a traditional herbal formula, has been widely used to recover fatigue or consumptive disease after an illness. Along with much attention to herbal formula, the concerns about the safety and toxicity have arisen. To establish the safety information, SHT was administrated in Crl:CD Sprague Dawley rats at a daily dose of 0, 1000, 2000, and 5000 mg/kg for 4 weeks. During the test periods, we examined the mortality, clinical observation, body weight change, food consumption, organ weights, hematology, serum biochemistry, and urinalysis parameters. No changes of mortality and necropsy findings occurred in any of the groups during the experimental period. In either sex of rats treated with SHT at 5000 mg/kg/day, changes were observed in food intake, reticulocyte, total bilirubin, some urinalysis parameters, and relative organ weights. The results indicated that SHT did not induce toxic effects at a dose level up to 2000 mg/kg in rats. This dosage was considered no observed adverse effect level (NOAEL) and was appropriate for a 13-week subchronic toxicity study.


Sign in / Sign up

Export Citation Format

Share Document